A method of treating an adult animal to successfully resist infectious diseases includes orally administering to the animal a mixture of an animal feed and the additive produced by the following process at the rate of one to two pounds of additive per ton of animal feed:

collecting bovine colostrum milk,

removing substantially all of the fat from the colostrum milk,

removing the casein from the colostrum milk to obtain bovine colosteral whey,

dialyzing the whey,

adjusting the pH of the dialysate to 4.0 to 4.5, precipitating the whey,

removing the supernatant from the precipitated whey,

clarifying the supernatant,

adding a water, saline and phenol mixture to the clarified supernatant to obtain the desired concentration,

sterilizing the mixture, and

drying the mixture.

Patent
   4377569
Priority
Jan 21 1980
Filed
May 19 1981
Issued
Mar 22 1983
Expiry
Mar 22 2000
Assg.orig
Entity
Small
28
2
EXPIRED
1. A method of treating an adult animal to successfully resist infectious diseases including orally administering to said animal a mixture of an animal feed and an additive at the rate of 1 to 2 pounds of additive per ton of animal feed: said additive produced by the process of
collecting bovine colostrum milk including antibodies particular to said infectious diseases,
removing substantially all of the fat from the colostrum milk,
removing the casein from the colostrum milk to obtain bovine colosteral whey,
dialyzing the whey,
adjusting the pH of the dialysate to 4.0-4.5,
precipitating the whey,
removing the supernatant from the precipitated whey,
clarifying the supernatant,
adding a water, saline and phenol mixture to the clarified supernatant to obtain the desired concentration,
sterilizing the mixture,
and drying the mixture.
2. The method of claim 1 wherein said adult animal is other than cattle.
3. The method of claim 1 wherein said infectious diseases include mastitis.
4. The method of claim 3 wherein the antibodies particular to mastitis are naturally occurring in the bovine colostrum milk.
5. The method of claim 1 wherein the mixture is air dried.
6. The method of claim 1 wherein the step of drying the mixture includes mixing said mixture with egg albumin to produce a resultant mixture, thereby stabilizing the mixture and maintaining the viability thereof, and freeze drying said resultant mixture.

This is a continuation-in-part application of my previous U.S. patent application Ser. No. 114,375 filed Jan. 21, 1980, now abandoned.

Bovine milk contains one or more proteins of the globulin group although the amount present is usually quite small. The globulin group is generally considered to be comprised of lactoglobulin or beta lactoglobulin. The globulin of milk is very important. Under certain conditions it enables a mother to transmit immunity toward certain infections to her suckling. This takes place during the first two or three days of the young animal's life.

During the first few days of lactation, the secretion of the mammary gland differs a great deal from that of normal milk. The secretion is called colostrum. The first colostrum is very rich in globulin and fills the special needs of the newborn animal. Among these is a need for globulin, for the blood of the newborn of many species contains much less than the normal amount of this protein. Colostrum is an important source of antibodies for the newborn. The antibodies may either be the globulins themselves or are associated with the globulins. Colostrum is generally believed to be important in the case of the cow, goat, sheep, pig and mare.

Whereas it has previously been known in the art to treat newborn calves no older than sixty days of age with colostrum milk, it has heretofore been believed that such treatment would be ineffective for adult animals. This is because the gut walls of a calf change at a very young age so as to prevent the passage of the relatively large antibodies through them. Consistent with the prior belief that colostrum should only be beneficial to the very young, it has been the usual practice for dairymen to simply dispose of the colostrum milk not knowing that it could be beneficial when used in the feed for adult animals as well.

In applicant's earlier U.S. Pat. No. 4,051,235, the method of preparing bovine colostrum is described. It has been found that the bovine colostrum of the earlier patent may be air dried and added to animal feeds without the necessity of injecting the colostrum into the animal.

As previously stated, colostrum milk has been shown to be an important factor in the resistance of infectious diseases in the young newborn which was nature's purpose for providing colostrum milk. The antibodies found in colostrum milk help the newborn fight diseases as well as protect them from future infection through immunal responses. It has also been found that a cow can be stimulated to produce certain antibodies to bacteria by injecting the cow before calving with antigens to the antibodies desired. Further, it has been found that a cow which has been subjected to many diseases during its lifetime will also have produced certain antibodies. When the cow calves, the first milk produced by the cow will contain antibodies to the stimulants as well as the normal environmental antibodies present in the mammary.

The colostrum milk is collected and the antibodies are removed therefrom and are manufactured into a dried product which may be added to animal feeds to benefit other animals which may be subjected to the diseases which the particular antibodies are peculiar to. Contrary to the prior beliefs of dairy scientists, the other animals which will benefit by having the dried colostrum product added to their feeds include both adult cattle as well as animals of other species such as the goat, sheep, pig and mare.

Assuming that the cow has either been injected with certain antigens or that the cow simply has the normally occurring antibodies in the colostrum milk, the colostrum milk is collected after calving. Preferably, the colostrum milk is collected and frozen until a suitable quantity has been collected to enable the process to be carried out. The freezing of the colostrum milk also aids in subsequent removal of the fat from the colostrum milk. Examples I and II are two examples wherein the antibodies were recovered from the colostrum milk. Example I is the preferred process of recovering the antibodies while Example II is an alternate method for recovering the antibodies.

The colostrum milk is collected and frozen. The milk is defatted by partially thawing the frozen milk and skimming the top liquid therefrom. The remaining milk is then completely thawed and centrifugally separated to remove as much of the remaining fat as possible.

The defatted colostrum milk is then precipitated by adding 1.5 mg of CaCl2 per liter of milk and by adding one tablet (1.5 gram) of commercially available rennin per liter of milk. The mixture is then thoroughly stirred. The solution is then heated to 20°-80° C. and again stirred. The solution is permitted to stand for 2-5 hours and the casein in the solution is then removed by filtration. The resultant solution is termed "bovine colosteral whey".

The whey is then dialyzed against tap water at 47° F. with saline added for approximately 96 to 120 hours. The pH of the dialysate is adjusted to 4.0 to 4.5 with acetic acid. The whey is then precipitated by placing the same in vats having a controlled temperature of 35°-65° F. The supernatant is siphoned off and centrifuged. The supernatant is then clarified by filtration. The titre of the solution is determined in conventional fashion and a water, saline and 0.3% Phenol mixture is added to make a final bovine IGG concentration of 100 mg%.

The solution is then passed through a water sterilizer (ultraviolet). The solution is then air dried until a powder-like product is achieved. The dry product is then added to animal feeds such as silage, etc., in the preferred proportion of 1 to 2 pounds of additive per ton of animal feed.

The colostrum milk is collected and centrifugally separated to remove as much of the fat as possible.

The defatted colostrum milk is then precipitated by adding 1.0-2.0 mg of CaCl2 per liter of milk and by adding 0.5-1.5 tablets of commercially available rennin per liter of milk. The mixture is then thoroughly stirred. The solution is then heated to 20°-80°C and again stirred. The solution is permitted to stand for 2-5 hours and the casein in the solution is then removed by filtration. The resultant solution is termed "bovine colosteral whey".

The whey is then dialyzed against tap water at 40°-54° F. with saline added for approximately 96 to 120 hours. The pH of the dialysate is adjusted to 4.0 to 4.5 with acetic acid. The whey is then precipitated by placing the same in vats having a controlled temperature of 35°-65° F. The supernatant is siphoned off and centrifuged. The supernatant is then clarified by filtration. The titre of the solution is determined in conventional fashion and a water, saline and 0.3% Phenol mixture is added to make a final bovine IGG concentration of 100 mg%.

The solution is then passed through a water sterilizer (ultraviolet). The solution is then air dried until a powder-like product is achieved. The product is then added to animal feeds in the preferred proportion of 1 to 2 pounds of additive per ton of animal feed.

The dry product of Examples I and II, when added to the animal feed, provides the animals with the necessary antibodies to enable the animal to successfully resist the diseases which the particular antibodies are peculiar to.

The effectiveness of bovine colostrum in the gut has been demonstrated by tests which show that as little as one ounce of colosteral whey destroys Coliform 99 bacteria in the gut of young calves. In tests in which five grams of the dry product of Examples I and II was fed with feed, sub-clinical mastitis has been successfully reduced 60% in three herds with a thirty cow average, using the CMT paddle test. Most sub-clinical mastitis was found to be caused by Staph, Strep combinations. There are naturally occurring antibodies to Staph and Strep in the colostrum milk obtained for producing the dry product described above.

As an alternative to air drying, a freeze drying process may be utilized but it is recommended that the colostrum be mixed with egg albumin to stabilize it and to maintain its viability. Accordingly, the antibodies can then be reactivated in the gut of an animal.

Thus it can be seen that the method of this invention accomplishes at least all of its stated objectives.

Plymate, Robert R.

Patent Priority Assignee Title
10064916, Jun 08 2006 DEC International NZ Limited Treatment method for microbial infection
10478493, Aug 31 2015 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients
10611828, Nov 23 2010 PANTHERYX, INC. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
10716850, Dec 31 2014 Wellin, Inc. Anti-inflammatory factor retentate, method of isolation, and use
4636384, Jun 03 1982 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
4644056, Sep 06 1984 GALAGEN, INC Method of preparing a solution of lactic or colostric immunoglobulins or both and use thereof
4732757, Feb 06 1978 Stolle Research and Development Corporation Prevention and treatment of rheumatoid arthritis
4816252, Apr 15 1985 New Zealand Dairy Board Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins
4834974, Jan 13 1986 New Zealand Dairy Board Immunologically active whey fraction and recovery process
4843065, Oct 24 1983 Method of producing products for use in the treatment of bacterial and/or virus infections
4897265, Jun 03 1982 STOLLE MILK BIOLOGICS, INC Method for treating disorders of the vascular and pulmonary systems
4919929, Feb 01 1984 STOLLE MILK BIOLOGICS, INC Mammal immunization
5017372, Apr 14 1986 HASTINGS, DONALD H Method of producing antibody-fortified dry whey
5106618, Jul 02 1987 STOLLE MILK BIOLOGICS, INC Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
5670196, Apr 12 1995 NU SKIN INTERNATIONAL, INC ; NU SKIN ENTERPRISES, INC Method for microfiltration of milk or colostral whey
5707678, Apr 12 1995 NU SKIN INTERNATIONAL, INC ; NU SKIN ENTERPRISES, INC Method for microfiltration of milk or colostral whey
5710132, Nov 04 1993 MOLLER, WOLFGANG; RUDNICK, DIEDTER; KOTHE, NORBERT; KLOFT, MICHAEL; LISSNER, REINHARD Use of bovine colostral milk as a preparation for the protection of the liver
5780028, Sep 20 1993 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
6068862, Jun 30 1993 Taiyo Kagaku Co., Ltd. Tea-derived feed additive and animal feed containing the same
6180099, Oct 28 1994 Metagenics, Inc. Method of using immunoglobulin and fiber-containing compositions for human health
6241983, Oct 28 1994 METAGENICS, INC Bacteria-and fiber-containing composition for human gastrointestinal health
6509444, Oct 22 1999 Board of Regents of the University of Nebraska Serum amyloid a isoform from colostrum
6667063, Jun 10 1998 Nutritional or therapeutic supplement and method
7214512, Oct 22 1999 TRITON ALGAL INNOVATIONS, INC Genomic mammary Amyloid a sequence
7368546, Jan 21 2003 Board of Regents of the University of Nebraska Human SAA3 nucleic acid molecule, protein, and methods of use for same
9701735, Nov 23 2010 PANTHERYX, INC Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
RE33403, Jun 03 1982 STOLLE MILK BIOLOGICS, INC Method for treating disorders of the vascular and pulmonary systems
RE33565, Feb 06 1978 STOLLE MILK BIOLOGICS, INC Prevention and treatment of rheumatioid arthritis
Patent Priority Assignee Title
3376198,
4051235, Apr 22 1976 Method of preparing bovine colostrum for use in treating livestock
Executed onAssignorAssigneeConveyanceFrameReelDoc
Date Maintenance Fee Events
Sep 22 1986M170: Payment of Maintenance Fee, 4th Year, PL 96-517.
Oct 23 1990REM: Maintenance Fee Reminder Mailed.
Mar 24 1991EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Mar 22 19864 years fee payment window open
Sep 22 19866 months grace period start (w surcharge)
Mar 22 1987patent expiry (for year 4)
Mar 22 19892 years to revive unintentionally abandoned end. (for year 4)
Mar 22 19908 years fee payment window open
Sep 22 19906 months grace period start (w surcharge)
Mar 22 1991patent expiry (for year 8)
Mar 22 19932 years to revive unintentionally abandoned end. (for year 8)
Mar 22 199412 years fee payment window open
Sep 22 19946 months grace period start (w surcharge)
Mar 22 1995patent expiry (for year 12)
Mar 22 19972 years to revive unintentionally abandoned end. (for year 12)